$ cat ./records/cepi-funded-nipah-virus-vaccine-candidate-enters-first-human-phas-2018.txt
CEPI Funded Nipah Virus Vaccine Candidate Enters First Human Phase 1 Trial
[RECORD.TXT] · cat --full
CEPI — co-founded at Davos 2017 with a $100 million Gates Foundation contribution — awarded up to $25 million to develop HeV-sG-V, a recombinant subunit Nipah virus vaccine. In March 2020, HeV-sG-V became the first Nipah vaccine to enter Phase 1 human trials, enrolling 192 adults at Cincinnati Children's Hospital. Results confirmed dose-dependent immune responses with no serious adverse events, establishing immunogenicity proof for potential reactive deployment against a pathogen with up to 75 percent case fatality rate in humans.
Source: https://cepi.net/cepi-funded-nipah-virus-vaccine-candidate-first-reach-phase-1-clinical-trial
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Grants $29.97 Million to COR-NTD for Lymphatic Filariasis and Schistosomiasis Operational Research
Next →
Gates Foundation Awards CureVac Grants to Develop mRNA Influenza and Malaria Vaccines
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.